Please assess the completion status of the following clinical trial:

Trial Title: A Study of VI-0521 for the Treatment of Obstructive Sleep Apnea / Hypopnea Syndrome in Obese Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Obese adults 30 - 65 years old (inclusive);~* Women of child-bearing potential must be using adequate contraception;~* BMI between 30 and 40 kg/m2 (inclusive);~* Diagnosis of OSA syndrome with Apnea/Hypopnea Index (AHI) of 15 or greater;~* Unwilling or unable to comply with CPAP treatment;~Exclusion Criteria:~* Known allergy or hypersensitivity to phentermine or topiramate;~* Sleep disorder other than OSA syndrome;~* Women who are pregnant, breast feeding, or intend to become pregnant during the study;~* Presence of unstable angina or heart failure corresponding to NYHA functional class III or IV;~* History of myocardial infarction or coronary revascularization within the past year; any history of stroke;~* Presence of any clinically significant abnormality on electrocardiogram;~* Use of any prescription CNS stimulants;~* History of cholecystitis or cholelithiasis unless treated by cholecystectomy;~* History of glaucoma or any past or present use of medications to treat increased intraocular pressure;~* Weight gain or loss of greater than 5 kg, use of a very low-calorie diet, or participation in a formal weight loss program (investigational or otherwise) within the past 3 months;~* Previous bariatric surgery;~* Shift workers or any subjects with a circadian rhythm disorder;~* Professional drivers or commercial pilots;~* History of nephrolithiasis;~* More than one lifetime episode of major depression;~* History of bipolar disorder, obsessive compulsive disorder, borderline personality disorder, psychotic depression, schizophrenia, schizoaffective disorder, or any other psychotic disorder; history of any psychiatric hospitalization;~* History of a seizure disorder; concurrent use of any anticonvulsant drug (other than assigned study drug);

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- VI-0521 (Type: EXPERIMENTAL): 15 mg Phentermine and 92 mg Topiramate
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).